Zevra Therapeutics Inc (ZVRA)
9.64
+0.06
(+0.57%)
USD |
NASDAQ |
Nov 25, 14:11
Zevra Therapeutics Gross Profit Margin (Quarterly): 37.67% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 37.67% |
| June 30, 2024 | 19.69% |
| March 31, 2024 | 94.89% |
| December 31, 2023 | 84.53% |
| September 30, 2023 | 95.03% |
| June 30, 2023 | 92.01% |
| March 31, 2023 | 96.06% |
| December 31, 2022 | 98.91% |
| September 30, 2022 | 95.09% |
| June 30, 2022 | 96.08% |
| March 31, 2022 | 99.80% |
| Date | Value |
|---|---|
| December 31, 2021 | 97.71% |
| September 30, 2021 | |
| June 30, 2021 | 91.66% |
| March 31, 2021 | 91.75% |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 90.71% |
| March 31, 2020 | 68.26% |
| December 31, 2019 | -41.35% |
| September 30, 2019 | 91.28% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-41.35%
Minimum
Dec 2019
99.80%
Maximum
Mar 2022
76.97%
Average
92.01%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 69.01% |
| Ionis Pharmaceuticals Inc | 99.20% |
| Vanda Pharmaceuticals Inc | 94.65% |
| BioCardia Inc | -- |
| Xeris Biopharma Holdings Inc | 74.95% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -159.9% |
| Return on Assets | -56.14% |
| Return on Invested Capital | -85.03% |
| Profit Margin (Quarterly) | -899.2% |
| Operating Margin (Quarterly) | -739.0% |
| Return on Net Operating Assets | -113.3% |